EVOLUTION OF HERD SARS-COV-2 HUMORAL IMMUNITY IN THE REPUBLIC OF BELARUS

A. Y. Popova, V. S. Smirnov, S. Egorova, Alexander Alexandrovich Tarasenko, A. M. Dashkevich, A. M. Milichkina, A. L. Skuranovich, I. V. Drozd, E. Zueva, E. Samoilovich, V. A. Ivanov, E. Ramsay, A. V. Gubanova, V. G. Drobyshevskaya, O. B. Zhimbaeva, Olga Aleksandrovna Petrova, A. Razumovskaya, I. A. Karaban, Tamara Vasilievna Amvrosyeva, N. P. Shmeleva, Lyudmila Vladimirovna Rubanik, A. Dronina, A. A. Totolian, I. Glinskaya
{"title":"EVOLUTION OF HERD SARS-COV-2 HUMORAL IMMUNITY IN THE REPUBLIC OF BELARUS","authors":"A. Y. Popova, V. S. Smirnov, S. Egorova, Alexander Alexandrovich Tarasenko, A. M. Dashkevich, A. M. Milichkina, A. L. Skuranovich, I. V. Drozd, E. Zueva, E. Samoilovich, V. A. Ivanov, E. Ramsay, A. V. Gubanova, V. G. Drobyshevskaya, O. B. Zhimbaeva, Olga Aleksandrovna Petrova, A. Razumovskaya, I. A. Karaban, Tamara Vasilievna Amvrosyeva, N. P. Shmeleva, Lyudmila Vladimirovna Rubanik, A. Dronina, A. A. Totolian, I. Glinskaya","doi":"10.15789/2220-7619-eoh-14440","DOIUrl":null,"url":null,"abstract":"Background. The course of the COVID-19 epidemic process depends on population immunity which prevents pathogen spread. Aim: to study an evolution of SARS-CoV-2 humoral immunity in the Belarusian population relative to COVID-19 pandemic dynamics. Materials and methods. The work was carried out according to a methodology for assessing herd immunity developed by Rospotrebnadzor (Russia) and the Belarusian Ministry of Health involving the St. Petersburg Pasteur Institute (SPPI) by taking into account the WHO recommendations. The study was approved by the Bioethics Committee of Belarus and the SPPI Bioethics Committee. Participant selection was carried out by questionnaire using a cloud (internet server) service. To monitor herd immunity, a cohort of 4,661 subjects (involved at all stages of seromonitoring) was formed from the total volunteer group. Study subjects were randomized into groups based on age (1-17, 18-29, 30-39, 40-49, 50-59, 60-69, 70+ years), geographic region, and occupation. For the detection of antibodies (Abs) against SARS-CoV-2 nucleocapsid (Nc) and S glycoprotein receptor-binding domain (RBD), relevant assay systems were used according to the manufacturers instructions. A four-stage study was conducted according to a unified scheme. Results. At stage 1 (pandemic month 15), herd immunity was mainly accounted for by Nc+RBD+ Ab status alone. By stage 2 (4 months later), its specific proportion decreased by 1.2-fold, whereas percentage of subjects solely bearing RBD-specific Abs increased by 1.7-fold. At stages 3 and 4 (9 and 19 months after the onset) vs. stage 2, percentage of subjects with RBD+Nc‒ decreased by 3.5%; the proportion of persons with Nc+RBD‒ Abs increased by 1.5-fold. The most important contributor in herd immunity turned out to be due to population vaccination, with coverage reaching 70% by stage 4. Among vaccines, compared with whole-virion, inactivated BIBP-CorV vaccine the Sputnik V and Sputnik Light vector were used most often. Conclusion. The evolution of herd SARS-CoV-2 humoral immunity included a series of changes in circulating Ab levels (Nc, RBD). The hybrid immunity formed helped to reduce the incidence of COVID-19 to sporadic level.","PeriodicalId":21412,"journal":{"name":"Russian Journal of Infection and Immunity","volume":"39 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Infection and Immunity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15789/2220-7619-eoh-14440","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background. The course of the COVID-19 epidemic process depends on population immunity which prevents pathogen spread. Aim: to study an evolution of SARS-CoV-2 humoral immunity in the Belarusian population relative to COVID-19 pandemic dynamics. Materials and methods. The work was carried out according to a methodology for assessing herd immunity developed by Rospotrebnadzor (Russia) and the Belarusian Ministry of Health involving the St. Petersburg Pasteur Institute (SPPI) by taking into account the WHO recommendations. The study was approved by the Bioethics Committee of Belarus and the SPPI Bioethics Committee. Participant selection was carried out by questionnaire using a cloud (internet server) service. To monitor herd immunity, a cohort of 4,661 subjects (involved at all stages of seromonitoring) was formed from the total volunteer group. Study subjects were randomized into groups based on age (1-17, 18-29, 30-39, 40-49, 50-59, 60-69, 70+ years), geographic region, and occupation. For the detection of antibodies (Abs) against SARS-CoV-2 nucleocapsid (Nc) and S glycoprotein receptor-binding domain (RBD), relevant assay systems were used according to the manufacturers instructions. A four-stage study was conducted according to a unified scheme. Results. At stage 1 (pandemic month 15), herd immunity was mainly accounted for by Nc+RBD+ Ab status alone. By stage 2 (4 months later), its specific proportion decreased by 1.2-fold, whereas percentage of subjects solely bearing RBD-specific Abs increased by 1.7-fold. At stages 3 and 4 (9 and 19 months after the onset) vs. stage 2, percentage of subjects with RBD+Nc‒ decreased by 3.5%; the proportion of persons with Nc+RBD‒ Abs increased by 1.5-fold. The most important contributor in herd immunity turned out to be due to population vaccination, with coverage reaching 70% by stage 4. Among vaccines, compared with whole-virion, inactivated BIBP-CorV vaccine the Sputnik V and Sputnik Light vector were used most often. Conclusion. The evolution of herd SARS-CoV-2 humoral immunity included a series of changes in circulating Ab levels (Nc, RBD). The hybrid immunity formed helped to reduce the incidence of COVID-19 to sporadic level.
白俄罗斯共和国群体sars-cov-2体液免疫的演变
背景。COVID-19的流行过程取决于人群免疫,它可以阻止病原体的传播。目的:研究白俄罗斯人群SARS-CoV-2体液免疫与COVID-19大流行动态的演变。材料和方法。这项工作是根据Rospotrebnadzor(俄罗斯)和白俄罗斯卫生部制定的群体免疫评估方法进行的,该方法涉及圣彼得堡巴斯德研究所(SPPI),并考虑到世卫组织的建议。该研究得到了白俄罗斯生物伦理委员会和SPPI生物伦理委员会的批准。参与者的选择是通过使用云(互联网服务器)服务的问卷进行的。为了监测群体免疫,从整个志愿者组中组成了4,661名受试者(参与血清监测的各个阶段)的队列。研究对象根据年龄(1-17岁、18-29岁、30-39岁、40-49岁、50-59岁、60-69岁、70+岁)、地理区域和职业随机分组。检测SARS-CoV-2核衣壳(Nc)和S糖蛋白受体结合域(RBD)抗体(Abs)时,按照生产厂家的说明书使用相关的检测系统。按照统一的方案进行了四阶段的研究。结果。在第1阶段(大流行第15个月),群体免疫主要由单独的Nc+RBD+ Ab状态决定。到第2阶段(4个月后),其特异性比例下降了1.2倍,而仅携带rbd特异性抗体的受试者百分比增加了1.7倍。在第3期和第4期(发病后9个月和19个月)与第2期相比,RBD+Nc -的受试者百分比下降了3.5%;Nc+RBD -抗体的比例增加了1.5倍。结果证明,群体免疫最重要的贡献因素是群体疫苗接种,到第4阶段覆盖率达到70%。在疫苗中,与全病毒粒子灭活BIBP-CorV疫苗相比,Sputnik V和Sputnik Light载体使用最多。结论。畜群SARS-CoV-2体液免疫的演变包括循环Ab水平的一系列变化(Nc, RBD)。形成的混合免疫有助于将COVID-19的发病率降低到散发水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信